BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class. BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The Company's initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).